|
USA-HI-KIHEI Azienda Directories
|
Azienda News:
- Band Therapeutics
Band Therapeutics, LLC Wholly-owned subsidiary of Guardian Therapeutics Inventor and development sponsor of BT200, a VWF binding aptamer in clinical development for treatment of hereditary bleeding disorders
- Band Therapeutics LLC - LinkedIn
Band Therapeutics LLC | 73 followers on LinkedIn Band Therapeutics is a wholly-owned subsidiary of Guardian Therapeutics
- Band Therapeutics LLC - Drug pipelines, Patents, Clinical trials - Synapse
Explore Band Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 1 literature, Disease Domain:Neoplasms, Hemic and Lymphatic Diseases, Technology Platform:Aptamers, Small molecule drug, Drug:Rondaptivon Pegol, Anti-IL-23 therapy(Band Therapeutics, LLC), Anti-GPC3 therapy(Band Therapeutics, LLC
- Band Therapeutics LLC (Band Therapeutics LLC) - 药物管线_专利_临床试验_投融营收_最新药物 . . .
了解Band Therapeutics LLC (Band Therapeutics LLC)公司的药物管线，治疗领域，技术平台，以及它的1项临床试和1篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，技术平台:适配体，小分子化药，药物:Rondaptivon Pegol，Anti-IL-23 therapy(Band Therapeutics, LLC)，Anti-GPC3 therapy(Band
- BAND THERAPEUTICS, LLC in Belmont, MA | Company Info Reviews - Bizapedia
Discover Company Info on BAND THERAPEUTICS, LLC in Belmont, MA, such as Contacts, Addresses, Reviews, and Registered Agent
- Patents Assigned to BAND THERAPEUTICS, LLC
Abstract: The present disclosure relates to treatment of bleeding disorders, in particular, hemophilia A (mild, moderate or severe hemophilia) and von Willebrand disease (VWD), Type 1 or Type 2 or Type 3, using VWF targeting agents such as a PEGylated anti-VWF aptamer, BT200
- Band Therapeutics, LLC Company Profile - Dun Bradstreet
Find company research, competitor information, contact details financial data for Band Therapeutics, LLC of Lexington, MA Get the latest business insights from Dun Bradstreet
- BT-200 Drug Profile - Ozmosi
BT-200 is being developed by Band Therapeutics for the treatment of patients with hereditary bleeding disorders (Sourced from: https: clinicaltrials gov ct2 show NCT04677803?term=BT-200 draw=2 rank=1)
- Breaking new ground in von Willebrand disease treatment
Band Therapeutics’ BT200 is currently in multiple clinical trials for different subtypes of von Willebrand disease – it is most advanced for type 2B where it’s in phase 3 and it’s in phase 2 for type 1 and 3 Nanotechnology could also prove to be an interesting alley for the bleeding disorder
|
|